Endocrinology Advisor Conclusion The 2025 GLP-1 guidelines reflect a paradigm shift in the management of type 2 diabetes, emphasizing the multifaceted benefits of these agents
& Simister, N
[1] Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations
Compounded semaglutide and tirzepatide maintain efficacy over 12+ months with well-characterized safety profiles
The study, published Monday in the journal Nature Medicine, is one of the first big-picture looks at the benefits and risks of these new drugs, which rapidly made an impact on health care, insurance coverage, the grocery industry, and even the economy of an entire country (Denmark, where Novo Nordisk, the maker of Ozempic and Wegovy is based.) These drugs have also been given partial credit for a recent dip in obesity rates in the US, which dropped in 2023 for the first time in over a decade
